Insider · CIK 0001712276
Ben R Taylor
cfoofficer
Files at RXRX (RECURSION PHARMACEUTICALS, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -5,396 | $3.41 | $18k | 1,071,462 | 26 d ago |
| Sep 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -7,057 | $4.83 | $34k | 804,169 | Sep 17, 2025 |
| Aug 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -11,908 | $5.64 | $67k | 811,226 | Aug 19, 2025 |
| Jun 16, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -7,057 | $4.92 | $35k | 823,134 | Jun 18, 2025 |
| May 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -11,908 | $4.25 | $51k | 830,191 | May 19, 2025 |
| Apr 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -26,571 | $5.10 | $135k | 842,099 | Apr 3, 2025 |
| Dec 19, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +370,343 | $0.00 | $0 | 844,210 | Dec 20, 2024 |
| Dec 19, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +740,686 | $0.00 | $0 | 740,686 | Dec 20, 2024 |
| Dec 16, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -15,668 | $6.04 | $95k | 480,924 | Dec 18, 2024 |
| Dec 17, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | FTax withholding Class A Common Stock | -7,057 | $6.95 | $49k | 473,867 | Dec 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.